MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells by Peaston, A E et al.
Neuroblastoma (NB) is the most common solid tumour in early
childhood and is thought to arise from primitive neural crest cells,
which eventually give rise to mature sympatho-adrenal tissues.
Infant necropsy studies and mass infant screening programs for
NB have demonstrated a subclinical incidence of the disease,
which is more than twice the clinical incidence, suggesting a high
rate of spontaneous tumour regression (Beckwith and Perrin,
1963; Woods et al, 1996). Several lines of evidence indicate that a
process of ganglionic differentiation may be a necessary precursor
to tumour regression and neuroblast cell death (Evans et al, 1976;
Shimada et al, 1984). Taken together these observations have
suggested the existence of tumorigenic factors for NB, which act
by blocking normal embryonal neural crest differentiation and cell
death. 
We, and others, have previously shown that poor patient prog-
nosis correlates with high-level expression of the Multidrug
Resistance-associated Protein gene (MRP1) in primary NB tumour
tissue (Norris et al, 1996; Matsunaga et al, 1998; Bader et al,
1999). MRP1 is a 190 kDa protein belonging to the superfamily of
ATP-binding cassette (ABC) transmembrane transporters, such as
P-glycoprotein (Pgp). Overexpression of MRP1 in vitro has been
associated with low-level resistance to a wide range of cytotoxic
agents, overlapping with the range of drugs to which Pgp confers
resistance (Cole et al, 1992, 1994). MRP1 knockout mice show
increased sensitivity to etoposide, decreased inflammatory
responses, and increased tissue glutathione (Lorico et al, 1997;
Wijnholds et al, 1997). Collectively, these data suggest that, like
Pgp, MRP1 functions as an export pump of cytotoxic xenobiotics
(Deeley and Cole, 1997). High-level MRP1 expression in NB
tumour cells may provide protection against cytotoxic chemo-
therapy, thereby mediating drug resistance in vivo. However, our
own studies indicated that tumour relapse was predicted by high-
level MRP1 expression in some patients with localised disease
who had not received chemotherapy. This observation led us to
examine the hypothesis that high-level MRP1 expression in malig-
nant neuroblasts may function as a resistance factor for neuritic
differentiation and cell death. 
MATERIALS AND METHODS 
Cell culture 
The NB cell lines BE(2)-C (BE), with amplified MYCN, and
SHSY-5Y (SY), with single copy MYCN, were the kind gift of
Dr J Biedler, Memorial Sloan-Kettering Cancer Center, New York,
NY, USA. The human mammary carcinoma cell line MCF7WT,
and its MRP1-amplified subline MCF7VP, were the kind gift of Dr
E Schneider, Wadsworth Center for Laboratories and Research,
Albany, New York, NY, USA. Cells were maintained at 37˚C, 95%
humidity, 5% CO2 in air, in Dulbecco’s Modified Eagle’s Medium
(Life Technologies, Grand Island, NY, USA) supplemented with 
L-glutamine and 10% fetal calf serum (Trace Biosciences Pty Ltd,
Sydney, Australia). Transfected cells were selected and subse-
quently grown with the additional supplement of 0.5 mg ml–1
Hygromycin B (Calbiochem-Novabiochem Pty Ltd, San Diego,
CA, USA). 
Growth rates and evidence of morphologic differentiation of
individual control and transfectant NB clones were determined
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using Trypan blue exclusion and morphologic evidence of neurite
extension, as previously described (Marshall et al, 1995). Cells
were treated with all-trans-retinoic acid (aRA) (Sigma Chemical
Company, St Louis, MO, USA), 9-cis-retinoic acid and 13-cis-
retinoic acid (kind gift of Hoffman LaRoche, Basel, Switzerland)
to final concentrations of 0.01, 0.1, 1 or 10 µ M. The percentage of
apoptotic cells was estimated by examination of cell morphology
as previously described (Lock and Stribinskiene, 1996). 
To examine cellular cytotoxicity, BE cells overexpressing
MRP1 were seeded in 96-well plates and growth inhibition deter-
mined after 72 hours continuous exposure to various concen-
trations of sodium arsenate (Baker, Biolab Scientific, Sydney,
Australia), using a microtitre-based assay with the Alamar Blue™
reagent (Astral Scientific, Sydney, Australia). Using a log scale for
molar concentration, data points from at least 2 replicate assays
were fitted to a spline curve, and ID50 values determined from the
curve as previously described (Haber et al, 1989). 
Plasmid constructs and transfections 
The pCEBV7-MRP1 (CEP  MRP1) episomal expression vector
containing the full length human MRP1 cDNA in sense orientation
was the kind gift of Dr SPC Cole, Cancer Research Laboratories,
Queen’s University, Kingston, Ontario, Canada. CEP was derived
from pREP7 (Invitrogen, San Diego, CA, USA) by substituting
a cytomegalovirus promoter for the Rous sarcoma virus long
terminal repeat (Cole et al, 1994). To create MRP1 antisense
constructs, CEP MRP1 cDNA was digested with HindIII, to
generate a 1.7 kb fragment including a short segment of the CEP
polylinker and 0–1633 bp of the 5′ end of the MRP1 cDNA, and a
1.3 kb fragment of the MRP1 cDNA from 1634 bp to 2962 bp.
After purification, each fragment was cloned into the HindIII
restriction enzyme site in the mammalian expression plasmid
pMEP, where cloned fragments are under the control of the human
metallothionein IIA promoter. While the human metallothionein IIA
promoter is inducible by heavy metals, we have found that in NB
cells a low level of constitutive expression of cloned sequences
also occurs. As an empty vector control for comparison with SY
MRP-AS clones, SY cells were stably transfected with the pREP
plasmid. The pREP plasmid is identical to the pMEP plasmid,
except that cloned cDNAs are under the control of the Rous
sarcoma virus long terminal repeat, instead of the human metal-
lothionein IIA promoter. In prior experiments, we have shown no
difference in the growth behaviour of untransfected BE or SY
cells, or BE and SY cells transfected with either the pREP or
pMEP empty vector. BE and SY cells were transfected by electro-
poration with empty vectors (CEP, REP, MEP), or plasmids
containing MRP1 cDNA in sense (MRP-S), or antisense (MRP-
AS) orientation, and transfectants were selected in Hygromycin B
and perpetuated as previously described (Marshall et al, 1995). 
RNA isolation and PCR 
Total cellular RNA was isolated (Chomczynski and Sacchi, 1987)
and used to make cDNA using Moloney murine leukaemia virus
reverse transcriptase (Life Technologies) and random hexanucleotide
primers. To evaluate the relative mRNA expression levels of MRP1
in MRP-S transfected cell lines, cDNA equivalent to 50 ng of mRNA
from each line was subjected to co-amplification of target (MRP1)
and control (β 2-microglobulin) gene sequences. The gene-specific
oligonucleotide primers for MRP1 and the β 2-microglobulin gene,
the PCR conditions and methods of estimating gene expression by
reverse-transcriptase PCR have been previously reported (Bordow et
al, 1994; Haber et al, 1994). To evaluate relative expression of Bcl-2
in MRP-AS cells, β 2-microglobulin was the control gene. 
Gene-specific PCR primers for Bcl-2 were B11S (5′ ACAA-
CATCGCCCTGTGGATGAC3′ ), and B12AS (5′ AGCCAGGAG
AAATCAAACAGAGG3′ ), which amplified a 132 bp sequence
from 1970 bp to 2102 bp of the Bcl-2 coding sequence. 
Protein isolation and immunoblotting 
To measure cellular MRP protein, crude membranes were
prepared as previously described (Grant et al, 1994). For other
immunoblotting experiments, whole cell lysates were prepared
from harvested cell pellets by incubation in RIPA buffer (50 mM
Tris.Cl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% Na
deoxycholate, 0.1% SDS) for 30 min on ice, with vortexing every
10 minutes. The lysate was clarified by centrifugation (14 g,
10 min, 4˚C) and the supernatant stored at –70˚C until further use.
Protein content was determined using the BCA Protein Assay Kit
(Pierce Chemical Co, Rockford, IL, USA) and samples adjusted to
equal protein content before use. 
Equal sample volumes were separated by SDS-PAGE, transferred
and immunoblotted using monoclonal anti-MRP1 antibody, MRPr1
(Signet Laboratories, Inc, Dedham, MA, USA), or polyclonal anti-
Bax, anti-Bcl-2, anti-Bcl-xL, and anti-actin antisera (PharMingen,
San Diego, CA, USA). After incubation of membranes in horse-
radish peroxidase-conjugated secondary antibodies, immunostained
bands were detected using chemiluminescent methods (ECL,
Amersham International Plc, Little Chalfont, Bucks, UK; or
SuperSignal Substrate, Western Blotting, Pierce Chemical Co)
with image collection on X-ray film (ECL) or by phosphorimager
(SuperSignal). Quantitation of immunostained bands was by
densitometry (X-ray film), or by image analysis of phosphorimage
data using Multi Analyst 1.02 software (Bio-Rad). Equal protein
loadings were checked by immunostaining with an anti-β -actin
rabbit polyclonal antibody, and, by visual inspection or densitom-
etry of duplicate gels stained with Coomassie Blue. 
Immunocytochemistry 
Cells grown on collagen-coated cover slips were fixed in 4%
paraformaldehyde in PBS, pH 7.4, rinsed 3 times in PBS, then
further treated with ice cold methanol for 15 minutes, followed by 2
rinses with PBS. After blocking, the cells were immunostained
with monoclonal antibodies directed against either synaptophysin
(anti-SVP-38 antibody, Sigma Chemical Company), or high molec-
ular weight neurofilament (anti-NF-200 antibody, Sigma Chemical
Company). Stained coverslips were mounted on slides using the
ProLong Antifade Kit (Molecular Probes, Inc). The slides were
examined using an LSM GB 200 laser scanning confocal micro-
scope (Olympus, Tokyo, Japan) with excitation wavelengths of 488
nm (Argon) and 543 nm (Helium). The images were collected elec-
tronically (1024 × 768 pixels) and analysed using NIH Image soft-
ware (W. Richards, National Institutes of Health, Bethesda, MD,
USA). To estimate relative cellular protein content, mean pixel
density of 5 images each containing 20 individual cells was calcu-
lated by measuring the mean pixel density of 20 identical sized
spots per image (excluding measurements made over the nucleus)
and subtracting it from the mean non-cellular background
measured in each image by the same method. 1566 AE Peaston et al
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Caspase activity assays 
Cytosolic lysates were used to estimate caspase activity by
cleaving the synthetic caspase-3 substrate, N-acetyl-Asp-Glu-
Val-Asp-p-nitroanilide (Ac-DEVD-pNA) (BIOMOL Research
Laboratories). Briefly, 1 × 107 cells were washed in ice cold PBS,
resuspended in 1 ml lysis buffer 3 (10 mM HEPES, pH 7.4; 10
mM NaCl; 25 µ gm l –1 phenylmethylsulfonyl fluoride; 1 µ gm l –1
leupeptin; 1 µ gm l –1 aprotinin) and incubated on ice for 30
minutes. The cells were then disrupted by repeated freeze/thawing,
ultracentrifuged at 100 000 g for 1 hour at 4˚C, and the resultant
cytosolic (S100) and crude nuclear/membrane/organelle (P100)
fractions stored separately at –70˚C after resuspension of the P100
in 1 ml lysis buffer 3. Protein content was determined using the
BCA Protein Assay Kit (Pierce Chemical Co, Rockford, IL, USA),
and samples adjusted to equal protein content. An aliquot of lysate
equivalent to 100 µ g of protein was added to 150 µ l of reaction
buffer (20 mM PIPES pH 7.2, 100 mM NaCl, 1 mM EDTA,
10% sucrose, 0.1% 3-([3-cholamidopropyl]dimethylyammonio)-
1-propanesulfonic acid (CHAPS), 20 mM 2-mercaptoethanol)
containing the peptide substrate (final concentration 100 µ M) in a
96-well plate. The absorbance of each well at 405 nm (A405) was
read both before and following a 1 hour incubation at 37˚C. Ac-
DEVD-pNA cleavage activity was measured as A405 h–1 mg
protein–1, and expressed as % Ac-DEVD-pNA cleavage or caspase
3 activity. Preliminary experiments had verified linearity of
response over time and protein concentration (data not shown). 
TUNEL labelling 
NB cells were stained using the In situ cell death detection kit
(Roche, Castle Hill, Australia). Briefly, cells were harvested, along
with their respective supernatants, and washed once with cold
PBS. A total of 5 × 108 cells were placed on a polylysine glass
slide for cytospin preparation. Following cytospin, the slides were
fixed in a 4% paraformaldehyde solution for 1 hour at room
temperature. The slides were subsequently rinsed with PBS and
incubated in a permeabilising solution (0.1% Triton X-100, 0.1%
sodium citrate) for 2 minutes at 4˚C. The slides were then rinsed
twice with PBS and dried. 50 µ l of the TUNEL reaction mixture was
added onto the slides, which were incubated at 37˚C for one hour.
The slides were subsequently rinsed 3 times in PBS before analysis
under a fluorescence microscope. 5 microscopic fields (> 100 cells),
in duplicate experiments, were counted in duplicate slides to deter-
mine the proportion of TUNEL positive or apoptotic cells. 
RESULTS 
Down-regulation of endogenous MRP1 expression in
NB cells 
The NB tumour cell lines, BE and SY, were transfected with vectors
constitutively expressing, in antisense, either a 1.3 kb (1634–
2962 bp) or a 1.7 kb (0–1633 bp) fragment of the human MRP1
cDNA. Following 2 separate transfection experiments for each cell
line, individual clones (MRP-AS) were isolated in Hygromycin B
and characterised for MRP1 expression (Figure 1A and 1B). There
was a significant difference between the growth rate of BE MRP-AS
clones, and control MEP cells (Figure 2). Compared with control
cells, BE MRP-AS clones were markedly growth inhibited, with day
7 cell counts ranging from 15% to 39% of controls. Similarly, SY
MRP-AS clones were markedly growth inhibited when compared
with controls. Morphologic analysis of BE MRP-AS clones demon-
strated marked spontaneous neurite formation (Figure 3). There was
a strong inverse correlation between MRP1 expression level and the
proportion of BE MRP-AS cells with neurites after 7 days in culture
when individual clones were compared (Figures 1 and 3). 
Increased expression of synaptophysin and high-molecular-
weight neurofilament are features of neuronally differentiated
cells (Jahn et al, 1985). Confocal microscopy and image analysis
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Figure 1 MRP1 protein expression in control, MRP-AS (A and B) and
MRP-S (C) clones for the BE(2)-C (BE) (A and C) and SH-SY5Y (SY)
(B) neuroblastoma cell lines. In each panel control lysates from untransfected
BE or SY cells, and, BE or SY cells stably transfected with empty vector
(CEP, REP or MEP) have been included on the immunoblot. MRP1 protein
expression in control cells has been compared with BE or SY clones stably
expressing either a partial MRP1 cDNA cloned in antisense (panel A and B)
or the full-length MRP1 cDNA in sense (panel C, clones MRP540 and 5512).
Cell membrane protein lysates from parental, empty vector control,
transfectant clones for BE or SY cells were size-fractionated, and then
immunoblotted for MRP1 expression using an antibody specifically recog-
nising MRP1 as described in Materials and Methods. As a control for high-
level MRP1 expression in MRP-S transfectants, membrane lysates from
MCF7 breast cancer cells (MCF7WT), and, MCF7 cells containing an ampli-
fied and overexpressed MRP1 gene (MCF7VP) were included in panel CMRP1 associates with cell death and differentiation 1567
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of immunostained cells demonstrated increased expression of
synaptophysin and high molecular weight neurofilament in BE
MRP-AS cells compared with untreated control cells (Figure 4).
The expression levels of synaptophysin and neurofilament in
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Figure 2 Growth characteristics of MRP-AS and control cells. Cells were
plated at equal density on day –1, cultured under standard conditions, and live
cells counted at days 7 for BE (A) or SY (B) transfectant cells. Trypan blue dye
exclusion was used to distinguish live cells. The values represent the mean of
experiments performed three times in duplicate. Bars, standard error of mean
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Figure 3 Assessment of neuritic morphology of BE MRP-AS and control
cells. Control (BE MEP) and BE MRP-AS cells were cultured under
standard conditions for 1 week, then the proportion of cells with neurite
development assessed as described in Materials and Methods. The 
values represent the mean of 3 experiments performed in duplicate. Bars,
standard error of mean. (A) Histogram demonstrating the proportion of
cells with neurites for control (BE MEP) and the indicated BE MRP-AS
clones. (B) and (C), representative photomicrographs (100 × magnification)
of BE MEP and MRP-AS clone 1.7.4, demonstrating neuritic morphology
typical of MRP-AS clones
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Figure 4 Expression of synaptophysin and high molecular weight neurofilament in untreated BE MRP-AS clones. As a positive control for expression of
synaptophysin (A–D) and neurofilament (E–H), control BE MEP cells (A and E) were cultured in the presence (B and F) of 1 µ M aRA. Untreated MRP-AS
clones 1.3 (C and G) and 1.7.4 (D and H) were immunostained for synaptophysin (C and D) or neurofilament (G and H) and examined by confocal microscopy 1568 AE Peaston et al
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untreated BE MRP-AS cells were equivalent to that seen in
control cells undergoing morphologic differentiation following
retinoid treatment (Figure 4). 
MRP-AS clones demonstrate enhanced spontaneous
cell death 
We used trypan blue staining to determine the proportion of dead
cells in culture one week after plating. BE and SY MRP-AS
clones all had a significantly higher proportion (0.5–2.5 fold) of
dead cells than control cells (data not shown). Cells grown on
slides in 2-well chambers were stained with Wright’s stain and
examined for apoptotic morphology. A proportion of MRP-AS
cells exhibited typical apoptotic morphology (Figure 5A), and, in
comparison with control MEP cells, MRP-AS clones had a higher
proportion of morphologically apoptotic cells (Figure 5B). To
confirm the presence of apoptosis in MRP-AS cells we evaluated
TUNEL positivity and Caspase 3 activation (Figure 6). MRP-AS
clones 1.3 and 22 exhibited a higher proportion of TUNEL-
positive cells compared to controls during log phase growth.
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Figure 5 Apoptosis induced by MRP-AS transfection. Cells grown on
chamber slides were stained with Wright’s stain and examined for
apoptotic morphology. (A) Representative photomicrograph showing
apoptotic BE MRP-AS clone 1.7.22 cells (arrows) surrounded by live cells
(400 × magnification). (B) Histogram showing apoptotic index of parental
(BE), control (BE MEP) and indicated MRP-AS clones. Values represent
the mean of at least 6 independent determinations for each clone as
described in Material and Methods. Bars, standard error of mean.
Differences in the apoptotic index between control and MRP-AS lines were
assessed by two-tailed unpaired means comparison. *P < 0.05; n.s., no
significant difference
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Figure 6 TUNEL labelling and Caspase 3 activation in MRP-AS cells. Control (BE MEP) and BE MRP-AS cells were cultured under standard conditions
for 1 week, then placed on a glass slide by cytospin preparation. (A) Representative photomicrographs showing an increase in TUNEL-positive cells
among MRP-AS clones 1.3 and 22. (B) A histogram showing the proportion of TUNEL-positive cells in the same cytospin preparations. More than 100 cells
were counted in 2 replicate experiments. (C) A histogram expressing Ac-DEVD-pNA cleavage or caspase 3 activity for MRP-AS clones 1.3 and 22
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The increase in TUNEL positivity was proportionately similar to
the increase in apoptotic bodies shown for these clones in Figure
5B. Caspase 3 activity was similarly increased in both clones.
Thus, in the MRP-AS transfectants, growth data, morphologic
and immunocytochemical evidence showed that down-regulated
MRP1 expression was associated with growth inhibition, neuritic
differentiation, and apoptosis. 
Bcl-2 protein expression is decreased in MRP-AS cells 
Differentiation and apoptosis have been linked to the level of Bcl-
2 expression in NB primary tumour tissue and cell lines (Hoehner
et al, 1995). We therefore examined Bcl-2 mRNA and protein
expression levels in the MRP-AS and control cells. Bcl-2 mRNA
expression levels were similar for control and MRP-AS clones
(Figure 7A). However, immunoblots showed that the MRP-AS
clones had markedly reduced Bcl-2 protein expression compared
with control MEP and parental BE cells (Figure 7B). Antisera
directed against Bcl-x
L and Bax demonstrated no significant differ-
ence in the expression levels of these proteins for MRP-AS and
control cells (Figure 7B). These results suggested that in the MRP-
AS clones, reduced Bcl-2 protein expression was due to a transla-
tional or post-translational mechanism. 
Ectopic MRP1 overexpression blocks the neuritogenic
effects of retinoic acid 
The BE cell line was transfected with a vector constitutively
overexpressing the full-length human MRP1 cDNA (BE MRP-
S). 2 clones (MRP-S-540 and MRP-S-5512) with an MRP1
expression level 2-fold higher than controls (Figure 1C), were
selected for further study. Control (BE CEP) and MRP-S cells
showed similar morphology and growth characteristics to
parental BE cells. To test the function of MRP1 in the MRP-S
cells, we performed cytotoxicity assays using the MRP1-specific
substrate, sodium arsenate (Cole et al, 1994). Compared with
controls, MRP-S transfectants had a 2.3-fold (P < 0.05) higher
resistance to the cytotoxic effects of sodium arsenate as
measured by ID50. 
To investigate the effect of increased MRP1 expression levels
on the capacity of NB cells for neuritic differentiation, control
and MRP-S cells were treated with aRA. We found that aRA
induced a similar level of concentration-dependent growth inhi-
bition in MRP-S, BE CEP and BE cells (Figure 8). However, the
MRP-S clones were markedly resistant to neurite formation
(Figure 8). Similar results were observed when the cells were
treated with 13-cis-retinoic acid or 9-cis-retinoic acid (data not
shown). 
DISCUSSION 
In this study, we have shown that the level of MRP1 protein
expression in NB tumour cells has unique effects on cell survival,
and on the capacity of NB cells to undergo neuritic differentiation
in vitro. Reduced MRP1 expression in MRP-AS cells correlated
with reduced Bcl-2 protein levels through a post-transcriptional
effect on Bcl-2 expression. Taken together, our results suggest the
hypothesis that high-level MRP1 expression, may be an acquired
characteristic of neuroblasts undergoing malignant transformation
in vivo, which contributes to the malignant phenotype by blocking
the developmentally regulated neuronal deletion which occurs
during embryogenesis of the neural crest. 
A link between MRP1 expression level, and protection against
cell death caused by substances other than chemotherapeutic cyto-
toxic drugs, has not been reported. However, recent studies indi-
cate that another membrane-associated efflux pump, Pgp, may
protect malignant cells against caspase-dependent apoptosis induced
by activation of Fas, serum deprivation, and other death-inducing
stimuli (Robinson et al, 1997; Smyth et al, 1998; Johnstone et al,
1999). Growth factors and other morphogens involved in neural crest
development are possible MRP1 export substrates. Embryonal
neuronal deletion is regulated by multiple neurotrophins in an age-
and cell type-specific manner (Davies, 1997). Thus far, basic
fibroblast growth factor, acting as a survival factor for Kaposi’s
and osteogenic sarcoma cells, is the only protein defined as an
MRP1 export substrate (Aggarwal and Gupta, 1998; Gupta et al,
1998). 
Our studies are the first to link MRP1 expression level with a
process of differentiation and cell death. Our previous findings
linking MRP1 expression levels in NB primary tumour tissue and
patient prognosis, combined with the data presented here, indicate
that MRP1 may play a role in the resistance of some NB tumour
cells to spontaneous regression. Further in vivo studies are
required to substantiate this hypothesis and to define the mecha-
nism of action of MRP1 in NB tumour cells. 
Figure 7 Expression of Bcl-2 in MRP-AS cells. (A) Histogram showing the
relative expression levels of Bcl-2 mRNA in control and MRP-AS cells
determined by semi-quantitative RT-PCR as described in the Materials and
Methods. Values quantifying mRNA expression are the mean (and standard
error of mean) of 3 independent experiments, where the ratio between the
densitometric value for Bcl-2 and the β -2-microglobulin PCR products was
determined. (B) Immunoblots showing protein expression levels of Bcl-2,
Bcl-xL, Bax and β -actin in control (BE MEP) and the indicated MRP-AS
clones
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